Current price is less than the intrinsic value

Intrinsic value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Ajanta Pharma gets US FDA nod for Fluphenazine Hydrochloride tablet

Ajanta Pharma gets USFDA nod for Fluphenazine Hydrochloride tablet

IOL Chemicals & Pharmaceuticals Ltd, Kaveri Seed Company Ltd, Suven Pharmaceuticals Ltd and Ajanta Pharma Ltd are among the other losers in the BSE’s ‘A’ group today, 26 December 2022.

Morepen Laboratories Ltd leads losers in ‘A’ group

Ajanta Pharma’s Promoters Sell 4.38% Stake: Entity, Transaction Details

Promoter entities of Ajanta Pharma on Thursday divested 4.3 per cent stake in the company for Rs 637 crore through open market transactions.

Ajanta Pharma promoter entities sell 4.3% stake for Rs 637 crore

Ajanta Pharma stock gained 4.01% to Rs 1219.20 against the previous close of Rs 1172.20 on BSE

Ajanta Pharma shares rise 4% amid reports of block deal

Jyothy Labs Ltd, Wockhardt Ltd, Sun Pharma Advanced Research Company Ltd and Ajanta Pharma Ltd are among the other gainers in the BSE’s ‘A’ group today, 22 December 2022.

Morepen Laboratories Ltd leads gainers in ‘A’ group

Ajanta Pharma Ltd witnessed volume of 70161 shares by 10:45 IST on BSE, a 33.54 times surge over two-week average daily volume of 2092 shares

Volumes jump at Ajanta Pharma Ltd counter

Ajanta Pharma will go ex-dividend today. The company had announced an interim dividend of Rs 7 per share. The record date for the same is November 14 and the dividend will be paid on December 3.

Ajanta Pharma, GMM Pfaudler to go ex-dividend; M&M, Hindalco, LIC Q2 results & more

Nifty futures on the Singapore Exchange quoted 317 points, or 1.75 per cent, higher at 18,414, hinting at a gap-up start for the domestic market on Friday.

SGX rallies 317 pts; LIC, Adani Power Q2 results; Inox Green IPO; Ajanta Pharma dividend & more

Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1560 in its research report dated November 04, 2022.

Buy Ajanta Pharma; target of Rs 1560: Motilal Oswal

Ajanta Pharma share price: The pharma company’s Q2 profit came at Rs 156.6 crore this year compared to a profit of Rs 195.94 posted in the year-ago period. The sharp plunge was mainly on account of higher expenses and lower sales in the US generics market.

Ajanta Pharma shares plunge 7% as profit slips in Q2

Ajanta Pharma Limited is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.

Ajanta Pharma Ltd

Ajanta Pharma Ltd

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Ajanta Pharma gets USFDA nod for Fluphenazine Hydrochloride tablet

Morepen Laboratories Ltd leads losers in ‘A’ group

Ajanta Pharma’s Promoters Sell 4.38% Stake: Entity, Transaction Details

Ajanta Pharma promoter entities sell 4.3% stake for Rs 637 crore

Ajanta Pharma shares rise 4% amid reports of block deal

Morepen Laboratories Ltd leads gainers in ‘A’ group

Volumes jump at Ajanta Pharma Ltd counter

Ajanta Pharma Ltd

Intrinsic valueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry pointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Ajanta Pharma gets USFDA nod for Fluphenazine Hydrochloride tablet

Morepen Laboratories Ltd leads losers in ‘A’ group

Ajanta Pharma’s Promoters Sell 4.38% Stake: Entity, Transaction Details

Ajanta Pharma promoter entities sell 4.3% stake for Rs 637 crore

Ajanta Pharma shares rise 4% amid reports of block deal

Morepen Laboratories Ltd leads gainers in ‘A’ group

Volumes jump at Ajanta Pharma Ltd counter

Intrinsic value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock